Почетна › Ulcerativni kolitis › Džordžija
Kliničke studije za Ulcerativni kolitis u državi Džordžija
13 studija za Ulcerativni kolitis traži učesnike na lokacijama u državi Džordžija.
Gradovi u državi Džordžija
Zvanični tekst studije (na engleskom)
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- Gastroenterology Associates of Central Georgia ( Site 1060), Macon
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 12. 11. 2026. · NCT07463183A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 4. 11. 2026. · NCT07483073A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Emory University, Atlanta
- Children's Center for Digestive Healthcare, Atlanta
Тражи се учесникФаза 3
Узраст 3 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06663332A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Atlanta Gastroenterology Specialists, Suwanee
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07577856A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Digestive Healthcare of Georgia, Atlanta
- AGA GA Research LLC, Atlanta
Тражи се учесникФаза 4
Узраст од 18 до 80 · Оба пола · Ажурирано 28. 10. 2026. · NCT06581328Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Associates of Central Georgia /ID# 280464, Macon
- Gastroenterology Consultants - Roswell /ID# 281235, Roswell
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 27. 10. 2026. · NCT07697456A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- Childrens Center For Digestive Health Care /ID# 273228, Atlanta
Тражи се учесникФаза 3
Узраст од 2 до 17 · Оба пола · Ажурирано 27. 10. 2026. · NCT07071519An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Atlanta Gastroenterology Associates - Site Number: 8400109, Atlanta
- M3 Wake Research - Atlanta - Site Number: 8400028, Sandy Springs
- EBGS Clinical Research Center, LLC - Site Number: 8400037, Snellville
- и још 1
Тражи се учесникФаза 3
Узраст од 16 до 80 · Оба пола · Ажурирано 23. 10. 2026. · NCT07184996A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Atlanta Gastroenterology Associates-Site Number: 8400109, Atlanta
Тражи се учесникФаза 3
Узраст од 16 до 80 · Оба пола · Ажурирано 16. 10. 2026. · NCT07185009A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Emory University School of Medicine, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
Тражи се учесникФаза 3
Узраст од 2 до 19 · Оба пола · Ажурирано 7. 10. 2026. · NCT04844606Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
- Gastroenterology Consultants, P.C., Roswell
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 21. 9. 2026. · NCT07513181A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
Тражи се учесникФаза 3
Узраст 2 и старији · Оба пола · Ажурирано 7. 5. 2026. · NCT05442567A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Atlanta
- Mirador Therapeutics Selected Site, Snellville
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 12. 3. 2026. · NCT07113522Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.